1 Emergence and rising of ceftazidime-avibactam resistant KPC-producing
2 *Pseudomonas aeruginosa* in China: a molecular epidemiology study

3 Yiwei Zhu^{1,2,3}, Jie Chen^{1,2,3,a}, Han Shen⁴, Zhongju Chen⁵, Qi-wen Yang⁶,
4 Jin Zhu⁷, Xi Li⁸, Qing Yang⁹, Feng Zhao¹⁰, Jingshu Ji¹⁰, Heng Cai^{1,2,3}, Yue
5 Li^{1,2,3}, Linghong Zhang^{1,2,3}, Sebastian Leptihn¹¹, Xiaoting Hua^{1,2,3},
6 Yunsong Yu^{1,2,3}

7 ¹Department of Infectious Diseases, Sir Run Run Shaw Hospital,
8 Zhejiang University School of Medicine, Hangzhou, China

9 ²Key Laboratory of Microbial Technology and Bioinformatics of
10 Zhejiang Province, Hangzhou, China

11 ³Regional Medical Center for National Institute of Respiratory Diseases,
12 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
13 Hangzhou, China

14 ⁴Department of Laboratory Medicine, Nanjing Drum Tower Hospital,
15 Nanjing University Medical School, Nanjing, China

16 ⁵Department of Laboratory Medicine, Tongji Hospital, Tongji Medical
17 College, Huazhong University of Science and Technology, Wuhan, China

18 ⁶Department of Laboratory Medicine and Beijing Key Laboratory for
19 Mechanisms Research and Precision Diagnosis of Invasive Fungal
20 Diseases, Peking Union Medical College Hospital, Chinese Academy of
21 Medical Sciences and Peking Union Medical College, Beijing, China

22 ⁷Department of Clinical Laboratory, Quzhou People's Hospital, Affiliated

23 Quzhou Hospital of Wenzhou Medical University, Quzhou, China

24 ⁸Centre of Laboratory Medicine, Zhejiang Provincial People's Hospital,

25 People's Hospital of Hangzhou Medical College, Hangzhou, China

26 ⁹State Key Laboratory for Diagnosis and Treatment of Infectious

27 Diseases, Collaborative Innovation Center for Diagnosis and Treatment

28 of Infectious Diseases, The First Affiliated Hospital, College of Medicine,

29 Zhejiang University, Hangzhou, China

30 ¹⁰Department of Clinical Laboratory, Sir Run Run Shaw Hospital,

31 Zhejiang University School of Medicine, Hangzhou, China

32 ¹¹The Zhejiang University-University of Edinburgh Institute, Zhejiang

33 University-Edinburgh University Institute, Zhejiang University,

34 International Campus, Haining, China; Department of Infectious Diseases,

35 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,

36 Hangzhou, China; School of Medicine, Edinburgh University, Edinburgh,

37 UK

38 ^aPresent address: Department of Laboratory, Ningbo Medical Center

39 Lihuili Hospital, Ningbo, China

40 Correspondence:

41 Xiaoting Hua address: No. 3, East Qingchun Rd, Jianggan District,

42 Hangzhou, China, 310016 [xiaotinghua@zju.edu.cn]

43 Yunsong Yu address: No. 3, East Qingchun Rd, Jianggan District,

44 Hangzhou, China, 310016 [yvys119@zju.edu.cn]

Background: Infections by Carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) are difficult to treat and novel antibiotics are desperately needed. Till today, ceftazidime-avibactam (CAZ-AVI) has been used to treat infections caused by multidrug resistant (MDR) Gram-negative bacteria, including *Klebsiella pneumoniae* carbapenemase (KPC)-producing organisms. Although cases of KPC-producing *P. aeruginosa* (KPC-PA) have been reported sporadically, data about KPC-PA susceptibility to CAZ-AVI and its molecular characteristics are limited.

Methods: CRPA were collected from seven hospitals in China from 2017 to 2018. PCR was deployed to screen for the *bla*_{KPC} gene. Antimicrobial susceptibility of KPC-PA was determined by broth microdilution method or agar dilution method. We combined Illumina sequencing and Nanopore long-read sequencing to elucidate the genomic characteristics of KPC-PA strains.

Results: KPC-PA strains were found in six out of seven hospitals. 151/374 (40.4%) CRPA clinical isolates harbored the *bla*_{KPC-2} gene. Among KPC-PA, ST463 (107/151) was predominant, followed by ST485 (14/151) and ST1212 (12/151). Approximately half of all KPC-PA (50.3%) were susceptible to CAZ-AVI. We found that the *bla*_{KPC-2} gene copy number correlated with CAZ-AVI MIC. In more than 90% (136/151) of the strains, we found plasmids that belonged to two types carrying

67 *bla*_{KPC-2} gene. The Type 1 plasmid, predominant in East China, was
68 identified in 118 strains and the Type 2 plasmid, belonged to a
69 megaplasmid family spreading globally, was identified in 19 strains. In
70 addition, we identified IS26- Δ Tn6296 and IS6100- Δ Tn6296-Tn1403 as
71 two mobile genetic elements that mediated *bla*_{KPC-2} gene transmission.

72 **Conclusion:** Our results suggest that the *bla*_{KPC-2} gene is becoming a
73 remarkable mediator of carbapenem resistance in *P. aeruginosa* in China.
74 The emergence and spread of such KPC-PA strains poses a threat on
75 clinical therapy as CAZ-AVI becomes inefficient. It would be beneficial
76 to screen for the *bla*_{KPC} gene in CRPA strains for antimicrobial
77 surveillance.

78 Keywords: *Pseudomonas aeruginosa*, *bla*_{KPC-2}, ceftazidime-avibactam

79

80 Background

81 *Pseudomonas aeruginosa*, one of major opportunistic pathogens, is
82 notorious for its potency to resist antibiotics including carbapenems.
83 Although carbapenems are still among the first-line therapeutics for
84 infections caused by multi-drug resistant (MDR) *P. aeruginosa*,
85 carbapenem-resistant *P. aeruginosa* (CRPA) are increasingly observed in
86 the clinic. Indeed, CRPA is among the pathogens listed by the World
87 Health Organization (WHO) that are considered of high relevance for
88 human health and for which new antibiotics or clinical strategies are

89 urgently needed [1].

90 Approved by the U.S. Food and Drug Administration (FDA) in 2015,
 91 ceftazidime-avibactam (CAZ-AVI), a novel β -lactam/ β -lactamase
 92 inhibitor combination, has been deployed in the clinic for complicated
 93 intraabdominal infections and for hospital-acquired pneumonia caused by
 94 multidrug-resistant *Enterobacteriaceae* and *P. aeruginosa* [2]. The
 95 inhibition spectrum of avibactam includes the *Klebsiella pneumoniae*
 96 carbapenemase family (KPC) [3]. According to INFORM surveillance
 97 [4-6], CAZ-AVI susceptibility rates are between 84-90% to CRPA that do
 98 not express metallo- β -lactamase (MBL). However, no study has detailed
 99 the CAZ-AVI susceptibility of KPC-PA as a single group, and
 100 investigated occurring resistance mechanisms, possibly due to the
 101 currently low prevalence of such strains. Perhaps unsurprisingly, an
 102 increasing number of *bla*_{KPC} genes have been detected in clinical *P.*
 103 *aeruginosa* isolates over the last years [7-12]. An example is the Eastern
 104 Chinese city of Hangzhou, where the rate of KPC-PA has increased
 105 significantly since the first case was reported a decade ago [13, 14].

106 Most of the investigated *bla*_{KPC} genes in *P. aeruginosa* have been
 107 reported to be plasmid-encoded [15-18], while a small number are found
 108 on the bacterial chromosome, occasionally in prophage sequences [12,
 109 19]. However, most of these studies are single case reports and focus on
 110 the description of the genetic structure of *bla*_{KPC} and its surrounding

111 sequences. Therefore, the importance of KPC-PA strains and their
112 relevance for the clinic remain unclear.

113 In this study, we analyzed the prevalence of KPC-PA strains from
114 seven hospitals in China and tested *in vitro* antimicrobial susceptibility.
115 We used Illumina and Nanopore sequencing technology to elucidate the
116 molecular epidemiology and genetic characteristics of the KPC-PA
117 strains.

118 Our data revealed that the susceptibility to CAZ-AVI of *Pseudomonas*
119 *aeruginosa* was 50.3% in China. We found that the distribution of
120 resistance genes was mediated by two major KPC-carrying plasmid types.
121 Our data showed that the *bla*_{KPC-2} gene copy number was associated with
122 CAZ-AVI MIC.

123 **Methods**

124 **Sample collection and antimicrobial susceptibility tests**

125 Clinical CRPA isolates were collected from seven hospitals around China,
126 including from Sir Run Run Shaw Hospital (SRRSH), the First affiliated
127 hospital of Zhejiang University (FAHZU), Provincial People's Hospital
128 of Zhejiang (ZPPH), Quzhou People's Hospital (QZPH), Nanjing Drum
129 Tower Hospital (NDTH), Wuhan Tongji Hospital (WTJH) and Peking
130 Union Medical College Hospital (PUMCH). Five hospitals were located
131 in Eastern China (SRRSH, FAHZU, ZPPH, QZPH and NDTH), while

other two (WTJH, PUMCH) were in Central and Northern China, respectively. All of these samples were isolated from patients between January, 2017 to February, 2018 and sent to SRRSH for investigation.

The *bla*_{KPC} gene was screened by PCR using the primers KPC-2_FW (5'-AGGTTCCGGTTTTGTCTC-3') and KPC-2_RV (5'-AGGTTCCGGTTTTGTCTC-3').

In vitro antibiotic susceptibility of 13 antipseudomonal antimicrobial agents was determined by broth microdilution or agar dilution method. The antibiotics included piperacillin-tazobactam, ceftazidime, cefepime, ceftazidime-avibactam, aztreonam, imipenem, meropenem, amikacin, gentamycin, tobramycin, ciprofloxacin, levofloxacin and colistin. Antimicrobial agents were prepared from commercially available sources. Breakpoints were referred to Clinical and Laboratory Standards Institute (CLSI) M100 [20]. *P. aeruginosa* strain ATCC 27853 and *K. pneumoniae* strain ATCC700603 was used as the quality control. Difficult-to-treat resistance (DTR) is defined as *P. aeruginosa* exhibiting non-susceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin, and levofloxacin [21].

Whole-genome sequencing

For each KPC-PA strain, a single clone was inoculated into 5 mL

153 Luria-Bertani broth and incubated in a 37°C shaker overnight. Bacteria
154 were lysed by FastPrep-24™ 5G bead beating grinder (MP Biomedicals,
155 CA, USA) at 6.0m/sec for 40 seconds twice. Genome DNA were
156 extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
157 according to the manufacturer. DNA concentration was quantified using a
158 NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA),
159 and verified by agarose gel electrophoresis. Libraries were prepared using
160 the TruePrep DNA Library Prep Kit V2 for Illumina (Vazyme Biotech,
161 Nanjing, China), and sequenced on an Illumina X Ten platform (Illumina
162 Inc., San Diego, CA, USA) and 150-bp paired end reads were generated.
163 The Illumina sequence data were *de novo* assembled by shovill v1.1.0 [22]
164 with options “--mincov 10 --minlen 200 --trim” and SPAdes v.3.13-v.3.14
165 [23] as the assembler.

166 To further investigate the molecular characteristics of KPC-PA, we
167 pursued Nanopore MinION long-read sequencing (Oxford Nanopore
168 Technologies, Oxford, UK) on 6 isolates (SRRSH1002, SRRSH1408,
169 NDTH10366, SRRSH15, WTJH12 and QZPH41). These isolates were
170 selected based on their sequence type, plasmid type, *bla*_{KPC-2} copy
171 number and geographic distribution. Another strain, SRRSH1101,
172 *bla*_{KPC-2}-negative but harboring Type 1 plasmid, also underwent Nanopore
173 sequencing to help illuminate the dynamics of multiple *bla*_{KPC-2} copies.
174 The raw reads of the sequenced isolates were mapped onto three

representative plasmid sequences (GenBank accession: KY296095.1, MN433457.1 and KU578314.1) by bwa-mem v.0.7.17 [24] to identify plasmid type. These plasmids were categorized into three types based on sequence similarity (cutoff is 50%).

Gene synteny

To attribute contigs to plasmid, genome draft of each strain was aligned to representative plasmid of each type by mummer v.4.0.0beta [25]. Results were filtered with a minimum length of 1000bp. The sum length of each contigs which matched with respective representative plasmid was calculated by a custom R script. Only contigs with more than 50% of length matched with representative plasmid were attributed to plasmid contigs. These plasmid contigs were re-annotated by Prokka v.1.14.6 [26], with representative plasmid as the prior source. Orthologs were found by Orthofinder v.2.4.0 [27]. Gene synteny was visualized by Cytoscape v.3.8.0 [28], according to a published script [29], with minute modification.

Sequencing depth measurement

To estimate the mean sequencing depth of each strain, SeqKit v.0.13.2 [30] was used to calculate total base amount in reads and genome drafts of each strain. Seqtk v.1.3-r106 [31] was used to subsample short reads

randomly to approximately 100× of sequencing depth. Short reads were
realigned to genome drafts by bwa-mem v.0.7.17 [24]. To assess the
chromosome sequencing depth, single copy gene regions were selected to
calculate their average depth with samtools v.1.11 [32] depth with option
“-aa”. These single-copy genes were derived from BUSCO v.4.0.0
Pseudomonadales ortholog database (10th edition) [33], which including
782 single copy genes. Each strain contained 776 (99.3%) single-copy
genes on average. Plasmid sequencing depth were represented by that of
repA gene. To assess the copy numbers of *bla*_{KPC-2} gene and two types of
plasmids, the ratio of sequencing depth of each gene to those of the
chromosome were calculated.

Phylogeny

P. aeruginosa genome drafts from NCBI Genbank database were
download. The MLST type was detected by mlst v.2.19.0 [34]. Isolates
with undefined sequencing type were submitted to PubMLST database
[35] for new ST profiles. Orthofinder v.2.4.0 [27] with default options
was used to cluster genes into orthologous groups. Sequences of single
copy orthologues were aligned by mafft v.7.471 [36] with options
(--maxiterate 1000 --localpair). Aligned genes of each strain were
concatenated by a custom script to finish the multiple sequence alignment.
The best nucleotide substitution models, GTR+I+G4, were selected by

ModelTest-NG v.0.1.6 [37] with option (-t ml). The maximum likelihood phylogenetic tree was generated by RAxML-NG v. 1.0.1 [38] with 100 tree searches (50 random and 50 parsimony-based starting trees) and bootstrap replicates (autoMRE criterion). TreeCollapseCL4 [39] was used to collapse branches with <50% bootstrap support into polytomies. A circular tree layout with associated matrix was constructed by the R package *ggtree* v.2.2.4 [40].

Acquired antimicrobial resistance genes and mutation-derived antibiotic resistance mechanism

Acquired antimicrobial resistance (AMR) genes were annotated by Abricate v.1.0.1 [41], using NCBI AMRFinderPlus database (April 29,2020 updated) [42]. Only antibiotic genes with coverage greater than 90% were included. Pseudomonas-derived cephalosporinase (PDC) and OXA-class β -lactamases were reexamined by BLASTX against amino acid sequences in NCBI AMRFinderPlus database.

To determine mutation-derived antibiotic resistance, a collection of 164 antibiotic-resistance-related genes derived from a previous study was selected as candidates to investigate [43]. Most of previous studies treated model species *P. aeruginosa* PAO1 as the reference. However, natural variations were common among different sequence types. To minimize the false positive results, we chose strains from a previous study as the

237 references for each ST. A published dataset containing both genome
238 sequences and antibiotic susceptibility results was treated as reference
239 [44]. One strain of each ST was selected from meropenem-susceptible
240 group in this dataset and our samples to compose an unduplicated set.
241 According to the accessory genes content analyzed by roary v.3.13.0 [45],
242 each representative strain of each ST in our sample paired with the most
243 similar strain in the meropenem-susceptible group for variant calling.
244 Variants were called by snippy v.4.6.0 [46], and only those in the 164
245 AMR gene regions were selected. Variants were filtered according to base
246 quality (Phred score) greater than 20 and minimum read depth greater
247 than 20. For *oprD* gene, signal peptide was predicted by SignalP v.5.0
248 portable version [47]. The *oprD* gene was inferred as nonfunctional if
249 signal peptide is absent or an early stopped mutation occurred.

250 **Statistical analysis**

251 All statistical analysis were performed using R v.4.0.0-v.4.0.2 and
252 Rstudio v.1.2.5001. Normality were detected by *shapiro.test* function in
253 stats package v.4.0.0. Gene copy number comparisons among different
254 MIC groups were done by *dunn.test* function in dunn.test package v.1.3.5,
255 between different plasmid type groups were performed by *wilcox.test*
256 function in stats package v.4.0.0. Correlation was calculated and tested by
257 *cor*, *cor.test* functions in stats package v.4.0.0, respectively.

258 Results

259 Geographic Distribution and Antimicrobial susceptibility

260 A total of 374 CRPA clinical isolates were collected from seven
 261 hospitals in China, those were SRRSH (n=86), FAHZU (n=71), WTJH
 262 (n=50), PUMCH (n=50), NDTH (n=44), ZPPH (n=35) and QZPH (n=35).
 263 151 strains were *bla*_{KPC}-positive based on PCR screens. All *bla*_{KPC} genes
 264 were *bla*_{KPC-2}. *bla*_{KPC-2} gene were detected in CRPA isolates from all
 265 hospitals except PUMCH. The percentage of *bla*_{KPC-2}-positive strains in
 266 CRPA varied among hospitals from 11.4% (NDTH) to 92.1% (ZPPH)
 267 (Figure 1). The antimicrobial susceptibility test on the 151 KPC-PA
 268 isolates showed high-level (>90%) resistance to fluoroquinolones and all
 269 β-lactams except to CAZ-AVI (Table 1). 93.4% (141/151) of isolates met
 270 the criteria of DTR. Half of isolates (76/151) were susceptible to
 271 CAZ-AVI. MIC_{50/90} of CAZ-AVI were 16/4 and 32/4 mg/L, respectively.
 272 The aminoglycosides resistance rates ranged from 4.0% to 8.6%. No
 273 strain was resistant to colistin. Three strains from NDTH were
 274 colistin-only-susceptible. Full AST results was shown in Supplementary
 275 Table 1.

276 Molecular epidemiology

277 Making use of Illumina sequencing data available for 151 KPC-PA, we

found that the multi-locus sequence type (MLST) detection indicated three main KPC-PA sequence types, ST463 (n=107), ST485 (n=14) and ST1212 (n=12), dominating in different geographic regions (Figure 1). ST463 was mainly found in cities in East China (Nanjing (5/5), Hangzhou (85/113) and Quzhou (17/19)), while ST485 (14/14) is the main KPC-PA of Wuhan in Central China (Figure 1).

Identification of KPC-encoding plasmids

Making use of sequence alignments, we categorized putative plasmid contigs in each genome draft into three plasmid types. 118 and 19 strains contained Type 1 and 2 plasmids, respectively. One strain, ZPPH8, contained both. No Type 3 plasmid was detected in our samples (Table 2 and Figure 2). The other 15 strains did not contain any of these three plasmid types.

Molecular characteristics of Type 1 plasmid

A representative of the Type 1 plasmid was pSRRSH1002-KPC. This plasmid was 49,370 bp in length and had a GC content of 58%. Encoded on pSRRSH1002-KPC was a putative repA, a maintenance system and an incomplete type IV secretion system (T4SS) which indicated that this plasmid was not conjugative *per se*. To visualize the structure variation of this plasmid type, we performed a gene synteny analysis which clustered

298 genes of the same orthologs and highlighted the variant part comparing to
299 the reference pSRRSH1002-KPC. From the gene synteny plot, we
300 observed two major variations. One variation we observed was that some
301 members of the Type 1 plasmid kept an intact T4SS. Another group was
302 formed that characterized by gene deletions and inversions in the
303 accessory region (Figure 3A).

304 Noticeably, pSRRSH1002-KPC harbored two *bla*_{KPC-2} gene copies. The
305 two *bla*_{KPC-2} adjacent regions laid in an inversed repeated pattern,
306 bounded by IS26. Each segment was identical to that on pKP048, the
307 most common prototype of *bla*_{KPC-2} adjacent region in China (Figure 3B)
308 [48]. Most often, the flanking insertion sequence was that of
309 IS26- Δ Tn6296. Tn6296 consisted of a core *bla*_{KPC-2} platform,
310 *Δ repB-orf1-klcA-orf2-korC- Δ kfrC- Δ ISKpn6-*bla*_{KPC-2}-ISKpn27-Tn2*
311 *tnpR- Δ Tn2 tnpA*, which inserted into Tn1722 [16]. The Tn2 *tnpA* gene
312 was truncated at the 2,456 bp site. Furthermore, an IS26 intramolecular
313 replicative transposition in *trans* truncated the Tn2 *tnpA* at the 81 bp site
314 and inverted a 6,922-bp segment as verified by an 8-bp target site
315 duplication (TSD, CGATATTT). Interestingly, different to other
316 IS26-franked tandem repeat arrays, both repeated segments were
317 separated by a Δ IS26 and an intact IS26. The first 294 bp of Δ IS26 was
318 deleted.

319 We sequenced other two more plasmids, pSRRSH1101 and

320 pSRRSH1408-KPC. pSRRSH1101 was 29,640-bp in size. It had the
321 identical backbone of pSRRSH1002-KPC. However, in pSRRSH1101,
322 the insertion region that contained *bla*_{KPC-2} gene was deleted (Figure 3C).
323 pSRRSH1408-KPC was identical with pSRRSH1002-KPC with the
324 exception of an IS26-mediated deletion of one *bla*_{KPC-2} gene (Figure 3C).

325 **Molecular characteristics of Type 2 plasmid**

326 pNDTH10366-KPC and pWTJH12-KPC belonged to a megaplasmid
327 family[49, 50], referred as Type 2 plasmid here. As with other family
328 members, these two plasmids carried a ParB-related ThiF-related cassette
329 (PRTRC system), a chemotaxis operon, a partition system, a type II
330 secretion system, a radical SAM operon, a tellurite resistance operon and
331 a T4SS on its backbone. The gene synteny plot illustrated the backbone
332 was stable and variable region was composed of different mobile genetic
333 elements containing multiple AMR genes including β -lactamases
334 *bla*_{KPC-2}, *bla*_{AFM} and *bla*_{OXA-246} (Figure 4).

335 **IS6100-related composite transposon mediated *bla*_{KPC-2} gene** 336 **transmission**

337 pWTJH12-KPC contained one *bla*_{KPC-2} gene. The genetic context
338 adjacent to *bla*_{KPC-2} was identical to that on the Type 1 plasmid with
339 p14057-KPC as a representative; in both plasmids the gene is embedded

in IS6100- Δ Tn6296-Tn1403 [16]. This suggested that this mobile genetic element (MGE) carrying *bla*_{KPC-2} might be able to transfer between two plasmid types, especially in case of ZPPH8 which contained both plasmids. The Type 2 plasmid containing the genetic context in which the *bla*_{KPC-2} was embedded, had been recently reported in Tianjin, China [18]. Interestingly, a sequence alignment showed that plasmid pNK546-KPC underwent large segment inversion next to the *bla*_{KPC-2} region (Figure 5). The similarities within the genetic contexts indicated frequent exchange events and transmission of *bla*_{KPC-2}-containing genome segments among the strains we investigated, despite of their different sequence types.

Comparison of two KPC-encoding plasmid types

Since most of the *bla*_{KPC-2} gene were located on plasmids, we hypothesized that plasmid types and plasmid copy numbers might contribute to the *bla*_{KPC-2} gene multiple copy in each strain. To verify our hypothesis, Illumina sequencing depths of all sequenced isolates were measured. Compared to Type 2 plasmid, Type 1 plasmid exhibited 1.2 more copies per cell (2.36 vs. 1.20, $p=1.5 \times 10^{-10}$, see Table 3). Strains containing Type 1 plasmid harbored 1.4 more *bla*_{KPC-2} gene on average than those containing Type 2 plasmid (2.56 vs. 1.15, $p=1.07 \times 10^{-7}$, see Table 3).

360 ***bla*_{KPC-2} gene on chromosome**

361 Although most *bla*_{KPC-2} genes were located on plasmids, we identified
362 two KPC-PA strains harbored *bla*_{KPC-2} gene on the chromosome.

363 In the *P. aeruginosa* strain NDTH10366, a *bla*_{KPC-2} gene array was
364 found on the chromosome which consisted of three IS26-mediated
365 tandem-repeat *bla*_{KPC-2} adjacent segments. Strains from SRRSH that
366 belonged to ST244, also contained a chromosome-embedded *bla*_{KPC-2}
367 gene. The genome of a representative strain SRRSH15 consisted of a
368 single circular 6.7-Mb-long contig. An IS6100-flanked composite
369 transposon with a size of 17,797 bp inserted into the chromosome at the
370 site of a putative hydrolase gene, leaving 8-bp TSD (GGCAAGCC)
371 (Figure 5). These findings indicated intracellular transposition occurred in
372 *P. aeruginosa* and participated in shaping *P. aeruginosa* genomes.

373 **The effect of the *bla*_{KPC-2} copy number and other AMR genes on** 374 **CAZ-AVI susceptibility**

375 In our samples, all strains exhibited high-level resistance to
376 carbapenems while the susceptibility to CAZ-AVI varied in a large range
377 (2-512mg/L). We further investigated the correlation between CAZ-AVI
378 MIC values and multiple *bla*_{KPC-2} gene copies mediated by both plasmid
379 multiple copies and IS26 or IS6100 duplicative transposition. We
380 excluded two strains containing MBLs (NDTH7329 and NDTH10366)

when analyzing the effect of the *bla*_{KPC-2} copy number on CAZ-AVI susceptibility. The *bla*_{KPC-2} gene copy number correlated with the CAZ-AVI MIC values (Pearson coefficient 0.326, 95% CI 0.174-0.463, $p < 0.0001$). Significant differences of the *bla*_{KPC-2} gene copy number were observed among CAZ-AVI MIC groups (2-32mg/L, Figure 6A). However, when values of the high-level resistance (≥ 64 mg/L) were observed, the relationship was less obvious, possibly due to the comparably fewer number of strains exhibiting high-level resistance to CAZ-AVI ($n=6$).

Besides the acquisition of *bla*_{KPC-2} gene, other chromosomal mutations also contributed to carbapenem and CAZ-AVI resistance. The *oprD* gene encoded the outer membrane porin D which allowed the diffusion of carbapenems into *P. aeruginosa*. In this study, all *oprD* genes could be classified into 18 types based on amino acid sequences similarity. 124/151(82.1%) strains were presumed to contain a nonfunctional *oprD* gene, mediating reduced sensitivity to carbapenems. The majority of nonfunctional *oprD* genes were found in ST463, ST244 and ST1212 strains. All *oprD* genes in the clinical isolates from WTJH and NDTH exhibit no mutations, indicating the expression of functional proteins (Figure 2 and Supplementary Table 2).

Carbapenem and CAZ-AVI resistance could also be mediated by the F533L mutation in the *ftsI* gene which encoded penicillin-binding protein 3 (PBP3) (Figure 2 and Supplementary Table 2). In 107 isolates that

403 belonged to ST463 strains, we found almost all of them (n=105)
 404 contained a T1597C nucleotide mutation in the *ftsI* gene, which lead to
 405 the F533L substitution in PBP3. All twelve ST1212 isolates displayed a
 406 so far uncharacterized mutation in the *ftsI* gene (A271G) and
 407 correspondingly T91A amino acid substitution in PBP3 which has not yet
 408 been studied regarding potential carbapenem or CAZ-AVI resistance
 409 mechanisms.

410 Since these variables such as mutations in PBP3 or porin D might
 411 contribute to the observed resistance values besides the acquisition of
 412 *bla*_{KPC-2} gene. In order to analyze the contribution of each variable to
 413 CAZ-AVI resistance, we analyzed the impact of *bla*_{KPC-2} gene copy
 414 number in a more homogenous genetic background. We selected a subset
 415 which consisted of 100 ST463 strains with the F533L substitution in
 416 PBP3 and nonfunctional porin D, while harboring the Type 1 plasmid. In
 417 this subset, significant difference was only detected between 8 and
 418 16mg/L groups (p=0.002, Figure 6B). Again, it might be explained by
 419 fewer samples in other groups.

420 We also investigated the effect of multiple *bla*_{KPC-2} genes copies on a
 421 single plasmid to CAZ-AVI susceptibility. We used the ratio of *bla*_{KPC-2}
 422 gene sequence depth to the *repA* gene sequence depth as the relative
 423 *bla*_{KPC-2} gene copies per plasmid. We defined the ratio less than 1.5 as
 424 single *bla*_{KPC-2} gene per plasmid (Single) and that greater than 1.5 as

multiple *bla*_{KPC-2} gene copies per plasmid (Multi) (Figure 6C and 6D). In 134 strains containing Type 1 or Type 2 plasmid, the CAZ-AVI MIC values were significantly different between the Single and the Multi groups ($p=1.6e-7$, see Table 4). This result was still hold in the ST463 subset mentioned above ($p=5.8e-5$, see Table 5). In both subsets, the plasmid copy numbers were not significantly different. Of note, the Multi group showed a right-shifting tendency of the CAZ-AVI MIC distribution compared to the Single group (Figure 6E and 6F). These results indicated that multiple *bla*_{KPC-2} gene copies caused by insertion-sequence-mediated duplication contributed to CAZ-AVI MIC elevation.

Other carbapenem or CAZ-AVI resistance related genes including *Pseudomonas*-derived cephalosporinase (PDC) and efflux pumps especially the MexAB-OprM. PDC was a constitutional β -lactamase in *P. aeruginosa* that was able to hydrolyze cephalosporins. PDCs were found to correlate with the sequence types. The *bla*_{PDC-8}, *bla*_{PDC-6}, *bla*_{PDC-3} genes were identified in three main STs, ST463, ST485 and ST1616, respectively. No amino acid substitutions which might contribute to CAZ-AVI resistance were detected in our samples. No so far known-of-function mutations in efflux pump genes was detected. In addition to *bla*_{KPC-2}, acquired β -lactamases observed in individual strains were *bla*_{CARB-2}, *bla*_{OXA-10} family β -lactamase *bla*_{OXA-246} and a novel MBL *bla*_{AFM}.

447 Comprehensive AMR-related mutations or acquired AMR genes were
448 listed in Supplementary Table 2.

449 Discussion

450 In this study, we focused on a specific subpopulation of CRPA, that
451 was KPC-PA. At the point of time when the bacteria were isolated, the
452 KPC-PA strains showed moderate susceptibility to CAZ-AVI. The MICs
453 of approximately 70% of the strains were at the margin of breakpoint
454 (8/4-16/4 mg/L). In our samples, we identified two main KPC-related
455 plasmids. Type 1 plasmid was predominant; however, most were found in
456 ST463 strains and their distribution was limited in Eastern China. In
457 contrast to this, Type 2 plasmid was spread more widely and existed in
458 many diverse sequence types. Deploying Nanopore long-read sequencing,
459 we deciphered *bla*_{KPC-2} genetic characteristics in this work. We found that
460 the *bla*_{KPC-2} copy number variation was caused by mobile genetic
461 elements, in particular by IS26, mediating transposition. Our results also
462 revealed that multiple copies of the *bla*_{KPC-2} gene correlated with elevated
463 CAZ-AVI MIC values.

464 Previous epidemiological surveillance studies had focused on CRPA.
465 One of the largest studies performed in China reported a resistance rate of
466 CRPA to CAZ-AVI was 34.3% in 2017 [51] and 35.7% in 2018 [52].
467 The strains investigated in our study were collected around the same time

(2017-2018). The isolated KPC-PA strains exhibited a higher CAZ-AVI resistance rate than all the CRPA. In the previous studies, no screening was performed regarding the *bla*_{KPC-2} gene, which in retrospect showed the unawareness of which important role this AMR gene played in *P. aeruginosa*. As for the origin of *bla*_{KPC-2} gene in *P. aeruginosa*, it was fair to infer that the gene was introduced into *P. aeruginosa* by interspecies transmission since the genomic environment of the *bla*_{KPC-2} gene was near identical and closely related to the gene that has first been described in *K. pneumoniae*. Data from the above-mentioned study [53] indicated that ~65 % carbapenem-resistant *K. pneumoniae* in China carried the *bla*_{KPC-2} gene, which made it the most prevalent carbapenemase in this species. Interestingly, 100% of *bla*_{KPC-2}-carrying *Enterobacteriaceae* were susceptible to CAZ-AVI [53], which stood in contrast to 50% susceptibility in KPC-PA which we observed in this study. It suggested that the acquisition of *bla*_{KPC-2} impacted the CAZ-AVI susceptibility in *P. aeruginosa* in more substantial extent than in *Enterobacteriaceae*. In general, it becomes clear that screening for *bla*_{KPC} in CRPA was important.

Our study also investigated the impact of *bla*_{KPC-2} copy number variation. It was reasonable to assume that there was a correlation between the *bla*_{KPC-2} copy number and CAZ-AVI resistance. Previous studies had demonstrated β -lactamase gene amplification correlated with

the susceptibility to β -lactam/ β -lactamase inhibitor combination agents [54-56]. Our results supported these conclusions. An important mechanism of AMR gene amplification was insertion-sequence (IS)-mediated duplication. In our study, *bla*_{KPC-2} was located on two mobile genetic elements, IS26- Δ Tn6296 and IS6100- Δ Tn6296-Tn1403. IS26-mediated module appeared to promote genetic element transposition, for example tandem or inversed repeats and from plasmid to chromosome. IS26 was strongly linked to horizontal AMR gene transfer [57]. Two mechanisms of IS26 movements had been demonstrated previously, that was the replicative transition and the conserved targeted transition [57, 58]. The characteristic 8-bp TSD can help to trace IS26 transposition. From our data, we could conclude that the *bla*_{KPC-2} copy number variation among strains harboring Type 1 plasmid was mediated by the conserved targeted transition. In later statistical study, we found that IS-mediated gene amplification contributed to CAZ-AVI MIC elevation. It caveated that the antimicrobial susceptibility test was necessary to surveil during the treatment course, since the MIC might fluctuate due to IS-mediated copy number variation.

Five *P. aeruginosa* plasmids carrying *bla*_{KPC-2} reported in China had been identified on the NCBI database (Table 2). Type 1 plasmid defined in this study was reported first by Shi et al [16] and later by Hu et al [17]. In this work, we provide high-precision sequencing data of three more

512 Type 1 plasmids with different *bla*_{KPC-2} gene copy numbers. Type 2
513 plasmids belonged to a megaplasmid family which had been reviewed
514 recently [49, 50]. Members of this family displayed a size of 300-500 Kb
515 and several AMR genes. However, those carrying *bla*_{KPC-2} genes were
516 only reported in China [18, 59]. The current study showed that this
517 megaplasmid spread widely around the country as we identified the
518 plasmid in Eastern and Central China. The third plasmid type, reported in
519 other publications, was not detected in this study, indicating that this
520 plasmid type might be not prevalent in regions we sampled. However,
521 two previously reported cases of the third plasmid type were found in
522 China in two different regions of the country [59], which suggested that
523 the third plasmid type was not rare. Fifteen strains in the current study
524 had undefined *bla*_{KPC-2} gene location (chromosome or plasmid). The
525 previously published data and our current work illustrates that a more
526 comprehensive surveillance study was required in the future to elucidate
527 the epidemiology of KPC-PA in China.

528 The two main plasmid types exhibited different geographical
529 distributions. This might be explained by the time that has passed since
530 the plasmids were incorporated by *P. aeruginosa* strains. Type 1 plasmids
531 had been found in *P. aeruginosa* for approximately one decade [13],
532 while the earliest strain harboring Type 2 plasmid could be traced back to
533 the 1980s [50]. In addition, the host range of Type 1 plasmid was

534 comparatively small, while the Type 2 plasmid family had been found in
535 other Pseudomonal and non-Pseudomonal genera [50]. This might be
536 explained by the fact that the conjugal ability of Type 2 plasmid has been
537 demonstrated experimentally [18], in contrast to Type 1 plasmids.
538 However, the high pressure of carbapenem usage in clinics might
539 accelerate the occurrence of *P. aeruginosa* harboring *bla*_{KPC-2} genes and
540 retain such strains in the nosocomial environment, leading to dominant
541 clones such as ST463.

542 The limited sampling locations of the strains, which originated mainly
543 from Eastern China, presents a limitation of our study, as the real
544 prevalence of KPC-PA over the whole country remained uncertain. As
545 discussed above, our investigation could be seen as a pilot study and thus
546 we highly recommended to screen for *bla*_{KPC} genes in nationwide
547 antimicrobial surveillance studies, or those being undertaking by other
548 nations. Another potential limitation was that we determined plasmids in
549 each strain by mapping sequencing reads to representative plasmids. We
550 understood that this approach did not guarantee to identify correctly on
551 which replicon the *bla*_{KPC-2} gene was located. However, we believed that
552 it was reasonable to assume that strains of the same ST were highly
553 similar in the genetic background to the representative strains that we
554 sequenced completely. Indeed, this approach had also been implemented
555 in a recent large-scale carbapenemase-harboring plasmid analysis [60].

556

557 Conclusions

558 In summary, our study clearly shows that KPC-PA strains represent a
559 threat to the healthcare system in China. Therefore, we propose to screen
560 *bla*_{KPC} genes in *P. aeruginosa* isolates in nationwide surveillance projects.
561 As this issue is not only affecting China but is of global concern, further
562 studies investigating the same topic on a global scale would help to
563 understand the epidemiology of KPC-PA strains in the entire human
564 population. We believe such studies might be able to guide therapeutic
565 deploying CAZ-AVI for the treatment of KPC-PA infections.

566

567 Declarations

568 Ethics approval and consent to participate

569 Approval was obtained from the Ethics Committee of Sir Run Run
570 Shaw Hospital (approval/reference number: 20201118-49). This study
571 was not considered as a human research. Therefore, no informed consent
572 to participate was required. This study conformed to the principles of the
573 Helsinki Declaration.

574 Consent for publication

575 Not applicable

576 Availability of data and material

577 All the sequence data were deposited at DDBJ/ENA/GenBank under
578 the BioProject accession number PRJNA672835.

579 **Competing interests**

580 The authors declare that they have no competing interests.

581 **Funding**

582 This study is supported by the National Natural Science Foundation of
583 China (grant no. 81830069).

584 **Authors' contributions**

585 Y.Y conceived, designed, and coordinated this study. Y.Z. and J.C.
586 performed the microbiological cultures of the isolates and antimicrobial
587 susceptibility tests. Y.Z and X.H. analyzed the genome sequencing data.
588 H.S., Z.C., Q.Y., J.Z., X.L, Q.Y. and F.Z. collected the isolates from
589 respective hospitals. J.J., H.C., Y.L. and L.Z. provided help to extract
590 genome DNA and perform genome sequencing. Y.Z. wrote the initial
591 version of the manuscript. X.H., S.L. and Y.Y. revised the manuscript. All
592 authors read and approved the final manuscript.

593 **Acknowledgments**

594 Not applicable

595

596

597 **References:**

- 598 1. Tacconelli E *et al.* Discovery, research, and development of new antibiotics: the WHO priority list
599 of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 2018, 18(3):318-327.
- 600 2. Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to Novel β -Lactam- β

601 -Lactamase Inhibitor Combinations. *Infect Dis Clin N Am* 2020, 34(4):773-819.

602 3. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam:

603 Second-generation β -Lactam/ β -Lactamase Inhibitor Combinations. *Clin Infect Dis* 2016,

604 63(2):234-241.

605 4. Karlowsky JA *et al.* In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of

606 *Enterobacteriaceae* and *Pseudomonas aeruginosa* Collected in Latin American Countries: Results

607 from the INFORM Global Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother* 2019,

608 63(4):e1814-e1818.

609 5. Karlowsky JA *et al.* In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of

610 *Enterobacteriaceae* and *Pseudomonas aeruginosa* Collected in Asia-Pacific Countries: Results from

611 the INFORM Global Surveillance Program, 2012 to 2015. *Antimicrob Agents Chemother* 2018,

612 62(7):e2517-e2569.

613 6. Kazmierczak KM, de Jonge B, Stone GG, Sahm DF. In Vitro Activity of Ceftazidime/Avibactam

614 against Isolates of *Pseudomonas aeruginosa* Collected in European Countries: INFORM Global

615 Surveillance 2012-15. *J Antimicrob Chemother* 2018, 73(10):2777-2781.

616 7. Villegas MV *et al.* First identification of *Pseudomonas aeruginosa* isolates producing a KPC-type

617 carbapenem-hydrolyzing beta-lactamase. *Antimicrob Agents Chemother* 2007, 51(4):1553-1555.

618 8. Naas T *et al.* Genetic structures at the origin of acquisition of the beta-lactamase bla_{KPC} gene.

619 *Antimicrob Agents Chemother* 2008, 52(4):1257-1263.

620 9. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. Emergence of KPC-producing

621 *Pseudomonas aeruginosa* in the United States. *Antimicrob Agents Chemother* 2010, 54(7):3072.

622 10. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-Driven β -Lactam Resistance

623 Mechanisms among Contemporary Ceftazidime-Nonsusceptible *Pseudomonas aeruginosa* Isolates

624 from U.S. Hospitals. *Antimicrob Agents Chemother* 2014, 58(11):6844-6850.

625 11. Hagemann JB, Pfennigwerth N, Gatermann SG, von Baum H, Essig A. KPC-2

626 carbapenemase-producing *Pseudomonas aeruginosa* reaching Germany. *J Antimicrob Chemother* 2018,

627 73(7):1812-1814.

628 12. Galetti R, Andrade LN, Varani AM, Darini ALC. A Phage-Like Plasmid Carrying bla_{KPC-2} Gene

629 in Carbapenem-Resistant *Pseudomonas aeruginosa*. *Front Microbiol* 2019, 10:572.

630 13. Ge C *et al.* Identification of KPC-2-producing *Pseudomonas aeruginosa* isolates in China. *J*

631 *Antimicrob Chemother* 2011, 66(5):1184-1186.

632 14. Hu Y, Gu D, Cai J, Zhou H, Zhang R. Emergence of KPC-2-Producing *Pseudomonas aeruginosa*

633 Sequence Type 463 Isolates in Hangzhou, China. *Antimicrob Agents Chemother* 2015,

634 59(5):2914-2917.

635 15. Naas T, Bonnin RA, Cuzon G, Villegas MV, Nordmann P. Complete sequence of two

636 KPC-harboring plasmids from *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 2013,

637 68(8):1757-1762.

638 16. Shi L *et al.* Coexistence of two novel resistance plasmids, bla_{KPC-2}-carrying p14057A and

639 tetA(A)-carrying p14057B, in *Pseudomonas aeruginosa*. *Virulence* 2018, 9(1):306-311.

640 17. Hu Y, Wang Q, Sun Q, Chen G, Zhang R. A novel plasmid carrying carbapenem-resistant gene

641 bla_{KPC-2} in *Pseudomonas aeruginosa*. *Infect Drug Resist* 2019, Volume 12:1285-1288.

642 18. Li Z *et al.* Molecular genetic analysis of an XDR *Pseudomonas aeruginosa* ST664 clone carrying

multiple conjugal plasmids. *J Antimicrob Chemother* 2020, 75(6):1443-1452.

19. Abril D *et al.* Genome plasticity favours double chromosomal Tn4401b-bla_{KPC-2} transposon insertion in the *Pseudomonas aeruginosa* ST235 clone. *Bmc Microbiol* 2019, 19(1):45.

20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing CLSI supplement M100. In., 30th edn. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2020.

21. Tamma PD *et al.* Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. *Clin Infect Dis* 2020, ciaa1478.

22. Seemann T. <https://github.com/tseemann/shovill>

23. Bankevich A *et al.* SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 2012, 19(5):455-477.

24. Heng L. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXiv* 2013:1303-3997.

25. Marçais G *et al.* MUMmer4: A fast and versatile genome alignment system. *Plos Comput Biol* 2018, 14(1):e1005944.

26. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014, 30(14):2068-2069.

27. Emms DM, Kelly S. OrthoFinder: phylogenetic orthology inference for comparative genomics. *Genome Biol* 2019, 20(1):238.

28. Shannon P *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003, 13(11):2498-2504.

29. Weisberg AJ *et al.* Unexpected conservation and global transmission of agrobacterial virulence plasmids. *Science* 2020, 368(6495).

30. Shen W, Le S, Li Y, Hu F. SeqKit: A Cross-Platform and Ultrafast Toolkit for FASTA/Q File Manipulation. *Plos One* 2016, 11(10):e163962.

31. Heng L. <https://github.com/lh3/seqtk>

32. Li H *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009, 25(16):2078-2079.

33. Seppely M, Manni M, Zdobnov EM. BUSCO: Assessing Genome Assembly and Annotation Completeness. *Methods Mol Biol* 2019, 1962:227-245.

34. Seemann T. <https://github.com/tseemann/mlst>

35. Jolley KA, Bray JE, Maiden M. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Res* 2018, 3:124.

36. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 2013, 30(4):772-780.

37. Darriba D *et al.* ModelTest-NG: A New and Scalable Tool for the Selection of DNA and Protein Evolutionary Models. *Mol Biol Evol* 2020, 37(1):291-294.

38. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. *Bioinformatics* 2019, 35(21):4453-4455.

39. Hodcroft E. <http://emmahodcroft.com/TreeCollapseCL.html>

40. Yu G, Smith DK, Zhu H, Guan Y, Lam TT. GGTREE: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol* 2017, 8(1):28-36.

- 687 41. Seemann T. <https://github.com/tseemann/abricate>
- 688 42. Feldgarden M *et al.* Validating the AMRFinder Tool and Resistance Gene Database by Using
- 689 Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob*
- 690 *Agents Chemother* 2019, 63(11):e419-e483.
- 691 43. Del BE *et al.* Genomics and Susceptibility Profiles of Extensively Drug-Resistant *Pseudomonas*
- 692 *aeruginosa* Isolates from Spain. *Antimicrob Agents Chemother* 2017, 61(11).
- 693 44. Kos VN *et al.* The Resistome of *Pseudomonas aeruginosa* in Relationship to Phenotypic
- 694 Susceptibility. *Antimicrob Agents Ch* 2014, 59(1):427-436.
- 695 45. Page AJ *et al.* Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 2015,
- 696 31(22):3691-3693.
- 697 46. Seemann T. <https://github.com/tseemann/snippy>
- 698 47. Almagro AJ *et al.* SignalP 5.0 improves signal peptide predictions using deep neural networks.
- 699 *Nat Biotechnol* 2019, 37(4):420-423.
- 700 48. Shen P *et al.* Novel Genetic Environment of the Carbapenem-Hydrolyzing-Lactamase KPC-2
- 701 among Enterobacteriaceae in China. *Antimicrob Agents Ch* 2009, 53(10):4333-4338.
- 702 49. Jiang X *et al.* Plasmids of novel incompatibility group Inc_{pRBL16} from *Pseudomonas* species. *J*
- 703 *Antimicrob Chemoth* 2020, 75(8):2093-2100.
- 704 50. Cazares A *et al.* A megaplasmid family driving dissemination of multidrug resistance in
- 705 *Pseudomonas*. *Nat Commun* 2020, 11(1):1370.
- 706 51. Yin D *et al.* Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of
- 707 the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical
- 708 Isolates of Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2019,
- 709 63(4):e2418-e2431.
- 710 52. Yang Y *et al.* In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam and Other
- 711 Comparators against Clinical Isolates of Enterobacterales, *Pseudomonas aeruginosa* and
- 712 *Acinetobacter baumannii*: Results from China Antimicrobial Surveillance Network (CHINET) in 2018.
- 713 *Antimicrob Agents Chemother* 2020:e1720-e1726.
- 714 53. Han R *et al.* Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among
- 715 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Front*
- 716 *Cell Infect Mi* 2020, 10:314.
- 717 54. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-Vaborbactam
- 718 Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing
- 719 *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2017, 61(12):e409-e420.
- 720 55. Schechter LM *et al.* Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam
- 721 Resistance in *Escherichia coli*. *Mbio* 2018, 9(2):e518-e583.
- 722 56. Coppi M *et al.* Ceftazidime-Avibactam Resistance Associated with Increased *bla*_{KPC-3} Gene Copy
- 723 Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 *Klebsiella pneumoniae*.
- 724 *Antimicrob Agents Chemother* 2020, 64(4):e1816-e1819.
- 725 57. Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile Genetic Elements Associated with
- 726 Antimicrobial Resistance. *Clin Microbiol Rev* 2018, 31(4):e17-e88.
- 727 58. He S *et al.* Insertion Sequence IS26 Reorganizes Plasmids in Clinically Isolated
- 728 Multidrug-Resistant Bacteria by Replicative Transposition. *Mbio* 2015, 6(3):e762.
- 729 59. Dai X *et al.* The IncP-6 Plasmid p10265-KPC from *Pseudomonas aeruginosa* Carries a Novel Δ

730 ISEc33-Associated *bla*_{KPC-2} Gene Cluster. *Front Microbiol* 2016, 7:310.
731 60. David S *et al.* Integrated chromosomal and plasmid sequence analyses reveal diverse modes of
732 carbapenemase gene spread among *Klebsiella pneumoniae*. *Proc Natl Acad Sci U S A* 2020,
733 117(40):25043-25054.

734

735

736

737 **Table 1** *In vitro* Antimicrobial Susceptibility Tests of KPC-producing *P. aeruginosa* from 6 Hospitals
738 in China

Antibiotics	MIC (mg/L)			percentage resistance
	MIC ₅₀	MIC ₉₀	MIC range	
piperacillin/tazobactam	>256	>256	4->256	99.34
ceftazidime	128	256	4->256	100.00
cefepime	>256	>256	2->256	99.34
imipenem	>128	>128	8->128	100.00
meropenem	>128	>128	1->128	100.00
aztreonam	>128	>128	4->128	100.00
ceftazidime/avibactam	16	32	1->64	50.33
amikacin	4	16	1->64	3.97
gentamycin	4	8	0.25->64	8.61
tobramycin	1	2	0.25->64	3.97
ciprofloxacin	>16	>16	0.12->16	94.04
levofloxacin	>32	>32	0.25->32	93.38
colistin	0.5	0.5	<0.03-2	0.00

739

740 **Table 2** Three main types of KPC-encoding plasmids in *P. aeruginosa* from China

Plasmid Type defined in this study	No. in this study	Inc type	Plasmid names (accession numbers in NCBI database)
Type 1	118	Undefined	p14057-KPC(KY296095) p1011-KPC2(MH734334)
Type 2	19	IncP-3-like	pNK546-KPC(MN433457)
Type 3	0	IncP-6	p10265-KPC(KU578314) p1(CP040685)

No. numbers; Inc: incompatibility

741

742 **Table 3** Comparison between strains containing Type 1 and Type 2 plasmids

	Type 1 (n=117)	Type 2 (n=17)	p value
plasmid copy	2.36 (1.93-2.98)	1.2 (1.15-1.29)	1.45E-10
<i>bla</i> _{KPC-2} gene copy	2.56 (2.03-3.49)	1.15 (1.06-1.30)	1.07E-07

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcoxon test.

743

744 **Table 4** Comparison between single and multiple *bla*_{KPC-2} gene copies per plasmid groups in 134
745 strains containing Type 1 or 2 plasmids

	Single (n=102)	Multi (n=32)	p value
log ₂ (CAZ-AVI MIC)	3 (3-4)	4 (4-5)	1.63E-07

plasmid copy	2.32 (1.72-2.90)	2.07 (1.75-2.45)	3.60E-01
--------------	------------------	------------------	----------

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcox test.

Table 5 Comparison between single and multiple *bla*_{KPC-2} gene copies per plasmid groups in 100 ST463 strains

	Single (n=70)	Multi (n=30)	p value
log ₂ (CAZ-AVI MIC)	4 (3-4)	4 (3-4)	5.80E-05
plasmid copy	2.39 (1.94-3.03)	2.09 (1.78-2.49)	0.1003

The medians are shown. In brackets indicate interquartile ranges. p values are calculated by Wilcox test.

Figure 1. Geographical distribution of strains in this study. The percentages in the figure represent the percentage of KPC-PA in CRPA from each hospital. Each pie size indicates sample size of each hospital. PUMCH: Peking Union Medical College Hospital; WTJH: Wuhan Tongji Hospital; NDTH: Nanjing Drum Tower Hospital; FAHZU: the First Affiliated Hospital of Zhejiang University; SRRSH: Sir Run Run Shaw Hospital; ZPPH: Provincial People's Hospital of Zhejiang; QZPH: Quzhou People's Hospital.

Figure 2. Core genome phylogenetic tree and carbapenem/CAZ-AVI resistance-related genes. Innermost layer is a maximum-likelihood phylogenetic tree of KPC-PA. colors of tip labels indicate sequence type (ST), and shapes indicate plasmid types in each strain. The unknown plasmid type suggests strain does not contain Type 1 or 2 plasmid and *bla*_{KPC-2} gene is located on another replicon. The second ring indicates cities where the strain is isolated. The next three rings indicate MICs of imipenem, meropenem and CAZ-AVI, respectively. The sixth ring represents loss-of-function mutation in *oprD* gene. The

766 seventh ring represents F533L mutation in PBP3. The eighth ring indicates estimated
767 *bla*_{KPC-2} gene copy number. The stars in the outmost ring indicate novel MBL *bla*_{AFM}.

768

769 **Figure 3. Type 1 plasmid schematic plot and sequence alignment. A. pSRRSH1002-KPC**

770 **structure and Type 1 plasmid gene synteny.** The innermost layer indicates gene synteny

771 of Type 1 plasmids. The arrows in second ring from the innermost indicate genes on

772 SRRSH1002, which are in accordant with points of the gene synteny layers. Orange

773 indicate transposase, red indicates *bla*_{KPC-2} gene, light-orange indicates genes in the

774 insertion region, green indicates conjugal elements, light-purple indicates *repA* gene. The

775 third ring shows backbone(grey) and insertion region(black) of the plasmid. The forth ring

776 represent GC skew, where yellow means skew to A and T and blue means skew to G and

777 C. The outmost ring represents GC content, where light-green represent GC% greater

778 than the median and dark-pink represents GC% less than the median (sliding window of

779 500bp). **B. Alignment of insertion regions on SRRSH1002-KPC and pKP048.** Arrows

780 denoted to genes or truncated genes. Alignment identity ranges from 97% to 100%.

781 GenBank accession: pRA3 (DQ401103), pKP048 (FJ628167), Tn4401 from pCOL-1

782 (KC609323), Tn2 (AY123253). **C. IS26-mediated *bla*_{KPC-2} gene copy number variation in**

783 **Type 1 plasmid.** Firstly, start from Precursor plasmid contained an IS26-flanked *bla*_{KPC-2}

784 region. An intramolecular replicative transposition in trans inversed the segment between

785 the 81th bp site on the ΔTn2 *tnpA* gene and an IS26 and duplicated an IS26 in opposite

786 orientation (precursor 2). Intramolecular replicative translocation in *cis* created a

787 translocatable unit (TU). The TU inserted into precursor 2 by conservative targeted

transposition to form pSRRSH1002-KPC. pSRRSH1002-KPC excised TU containing the repeated genetic segments and the Δ Tn2 *tnpA* gene to form pSRRSH1101. Another plasmid precursor 3 excised a TU containing a *bla*_{KPC-2} gene by intramolecular replicative translocation in *cis* to form pSRRSH1408-KPC.

792

Figure 4. pWTJH12-KPC plasmid structure and gene synteny. The innermost layer indicates gene synteny of Type 2 plasmids. The second ring represent GC skew, where yellow means skew to A and T and blue means skew to G and C. The third ring represents GC content, where light-green represent GC% greater than the median and dark-pink represents GC% less than the median (sliding window of 2000 bp). The forth ring shows backbone (grey) and accessory region (black) of the plasmid. The arrows in outermost ring indicates genes on pWTJH12-KPC, which are in accordant with points of the gene synteny layers. PRTRC: ParB-related ThiF-related cassette; SAM: *S*-adenosylmethionine; T2SS: Type II secretion system.

802

Figure 5. Alignment of IS6100- Δ Tn6296-Tn1403 structure from multiple strains. Arrows denoted to genes or truncated genes. Alignment identity ranges from 99% to 100%. GenBank accession: p14057-KPC(KY296095), pNK546a (MN433457).

806

Figure 6. Statistical analysis of the correlation between *bla*_{KPC-2} gene and CAZ-AVI MIC. A. *bla*_{KPC-2} gene copy number comparison among strains (n=149) with different CAZ-AVI MIC groups. The asterisks, *, **, ***, represent adjusted p-values of Dunn test less than

810 0.05, 0.01, 0.001, respectively. Two strains containing metallo- β -lactamase are not
811 involved. **B.** *bla*_{KPC-2} gene copy number comparison among ST463 strains (n=100) with
812 different CAZ-AVI MIC groups. The asterisk, **, represents adjusted p-values of Dunn test
813 less than 0.01. **C.** Correlation between *bla*_{KPC-2} gene copy number and plasmid copy
814 number in strains containing Type 1 or Type 2 plasmid (n=134). **D.** Correlation between
815 *bla*_{KPC-2} gene copy number and plasmid copy number in ST463 strains containing Type 1
816 plasmid (n=100). Each solid line indicates that points near it exhibit a *bla*_{KPC-2} gene to
817 plasmid copy number ratio as the slope (r). The red dashed line with a slope of 1.5
818 distinguishes single and multiple *bla*_{KPC-2} gene copies per plasmid. **E.** The CAZ-AVI MIC
819 distributions of strains (n=134) containing single *bla*_{KPC-2} gene or multiple *bla*_{KPC-2} gene
820 copies per plasmid. Both types of plasmids are included. **F.** The CAZ-AVI MIC
821 distributions of strains (n=100) containing single *bla*_{KPC-2} gene or multiple *bla*_{KPC-2} gene
822 copies per Type 1 plasmid. Blue and red bars represent the Single and the Multi group,
823 respectively.
824

A

C

B